Discover Daxor Corporation’s Groundbreaking Findings from Duke University: Key BVA Insights Unveiled at ACC’s 74th Annual Scientific Session & Expo

Daxor Corporation Highlights Blood Volume Measurement at Major Cardiology Conference

Oak Ridge, TN, April 02, 2025 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR) showcased its blood volume measurement technology at the American College of Cardiology’s 74th Annual Scientific Session in Chicago, drawing significant attention from over 400 clinicians. New findings from Duke University Medical Center emphasized that blood volume analysis (BVA) offers a more accurate understanding of heart failure than traditional pressure measurements.

During a bustling session titled, “When Pressure ≠ Volume: Understanding Complex Hemodynamic Situations and Pitfalls,” Dr. Marat Fudim of Duke University pointed out a critical issue: pressure-based assessments often misinterpret the true volume status of heart failure patients. This session illustrates the rising recognition of BVA within the cardiology community. “The attendance speaks volumes about the growing importance of direct volume measurement in patient care,” stated Michael Feldschuh, Daxor’s President and CEO.

Duke’s research also revealed some surprising results. Common indicators like urine output, weight changes, and specific biomarkers such as CA-125 and NT-proBNP did not correlate with actual blood volume levels. “This reinforces the need for precise volume management in heart failure treatment,” said Dr. John L. Jefferies, Daxor’s Chief Medical Officer. He emphasized that BVA delivers essential clarity for clinicians, allowing them to make better treatment decisions and improve patient outcomes.

In a recent survey, 70% of cardiologists expressed confusion over volume assessment methods, highlighting a significant gap in understanding. The reliance on indirect markers can lead to misdiagnoses, which could adversely affect patient care. Experts are calling for a shift toward more reliable methods like BVA to address these issues. As heart failure affects millions globally, improving measurement techniques could have a substantial impact on treatment success rates.

About the ACC

The American College of Cardiology (ACC) strives to enhance cardiovascular care worldwide through community, research, and education. With a network of over 56,000 members, it remains at the forefront of advancing heart health. Learn more at https://www.acc.org/.

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR) leads in blood volume measurement innovation. Its BVA-100® (Blood Volume Analyzer) is the only FDA-cleared diagnostic test for accurately assessing blood volume status. Over 65,000 tests have been conducted at top hospitals in the U.S., improving treatment strategies for various conditions, especially heart failure. Daxor aims to enhance healthcare through superior fluid management and continues to support research in heart failure treatment alongside the NIH. To know more about Daxor, visit Daxor.com.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com

Check out this related article: Exclusive Bloomberg Interview: Princeton’s Eisgruber Stands Firm, No Concessions on Key Issues

Source link

Nasdaq:DXR, Daxor Corporation, DXR, BVA, BVA-100, ACC2025